Publications by authors named "Marzia A Locatelli"
Background: Elderly patients are underrepresented in clinical trials, particularly in early-phase studies. Our study assessed the safety and efficacy of novel anti-cancer treatments investigated in early-phase clinical trials, comparing outcomes between younger and elderly patients.
Methods: This retrospective study analyzed data from patients enrolled in phase I/II trials at our center between January 2014 and April 2021.
Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6is) in combination with Endocrine Therapy (ET) represent the standard frontline therapy for patients with Hormone Receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic Breast Cancer (mBC). Clinical activity and efficacy of CDK4/6is-based therapies have been proven both in the endocrine sensitive and resistant settings. Therapy resistance eventually underpins clinical progression to any CDK4/6is-based therapies, yet there is a lack of validated molecular biomarkers predictive of either intrinsic or acquired resistance to CDK4/6is in clinical practice.
View Article and Find Full Text PDFTriple-negative breast cancer (TNBC) represents a heterogeneous breast cancer subtype with a poor prognosis. The optimal adjuvant chemotherapy regimen is still unknown. Although numerous large randomized trials have established the benefit of adjuvant anthracyclines and/or taxanes in TNBC, there is no preferred regimen for these patients.
View Article and Find Full Text PDFArticle Synopsis
- The study investigated PF-03084014, a selective gamma-secretase inhibitor, in combination with docetaxel for treating advanced triple-negative breast cancer, focusing on dosage and safety outcomes.* -
- A total of 29 patients were treated, determining the maximum tolerated dose to be PF-03084014 100 mg twice daily with docetaxel 75 mg/m², which was generally well-tolerated with manageable side effects.* -
- Results showed a 16% response rate with four patients achieving a confirmed partial response, while the median progression-free survival was 4.1 months, indicating limited efficacy but significant safety.*
Objectives: To assess efficacy of bevacizumab in combination with oral chemotherapy in patients with breast cancer with lymphangitic spread to the chest wall (LBC). To identify surrogate biomarkers of response to bevacizumab.
Patients And Methods: We randomly assigned patients to receive bevacizumab plus either sequential or concurrent oral vinorelbine and capecitabine every 3 weeks.
Recent evidence suggests that the immune system is involved in the carcinogenesis process and the antitumor immune responses impact the clinical outcome, thus emphasizing the concept of cancer immune surveillance. In this context, dendritic cells (DCs) seem to play a crucial role, as they are the most potent antigen-presenting cells (APCs) and are able to stimulate naive T lymphocytes and to generate memory T lymphocytes. Immunotherapy with DC-based vaccines is a very attractive approach to treat cancer, offering the potential for high tumor-specific cytotoxicity.
View Article and Find Full Text PDFArticle Synopsis
- Literature indicates that HER2/neu positive breast cancer is more responsive to radiation therapy, especially when targeting specific receptors.
- A study involving 466 patients with HER2/neu positive tumors compared outcomes from three treatment methods: quadrantectomy plus conventional radiotherapy, quadrantectomy plus intra-operative radiotherapy, and mastectomy without radiotherapy.
- After an average follow-up of over four years, results showed varying 5-year recurrence rates, highlighting the effectiveness of external radiotherapy combined with trastuzumab, while emphasizing the need for better risk stratification based on hormonal receptor status.